- Home
- SWBI vs RGNX Comparison
SWBI vs RGNX Comparison
Compare SWBI & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWBI
- RGNX
- Stock Information
- Founded
- SWBI 1852
- RGNX 2008
- Country
- SWBI United States
- RGNX United States
- Employees
- SWBI N/A
- RGNX N/A
- Industry
- SWBI Ordnance And Accessories
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SWBI Industrials
- RGNX Health Care
- Exchange
- SWBI Nasdaq
- RGNX Nasdaq
- Market Cap
- SWBI 429.0M
- RGNX 451.1M
- IPO Year
- SWBI N/A
- RGNX 2015
- Fundamental
- Price
- SWBI $9.35
- RGNX $9.28
- Analyst Decision
- SWBI Buy
- RGNX Strong Buy
- Analyst Count
- SWBI 2
- RGNX 8
- Target Price
- SWBI $12.00
- RGNX $28.50
- AVG Volume (30 Days)
- SWBI 1.1M
- RGNX 623.2K
- Earning Date
- SWBI 09-04-2025
- RGNX 11-05-2025
- Dividend Yield
- SWBI 5.54%
- RGNX N/A
- EPS Growth
- SWBI N/A
- RGNX N/A
- EPS
- SWBI 0.26
- RGNX N/A
- Revenue
- SWBI $471,404,000.00
- RGNX $155,782,000.00
- Revenue This Year
- SWBI N/A
- RGNX $260.25
- Revenue Next Year
- SWBI $9.23
- RGNX N/A
- P/E Ratio
- SWBI $35.69
- RGNX N/A
- Revenue Growth
- SWBI N/A
- RGNX 74.95
- 52 Week Low
- SWBI $7.73
- RGNX $5.04
- 52 Week High
- SWBI $14.20
- RGNX $13.48
- Technical
- Relative Strength Index (RSI)
- SWBI 72.61
- RGNX 52.85
- Support Level
- SWBI $8.57
- RGNX $9.15
- Resistance Level
- SWBI $9.77
- RGNX $10.08
- Average True Range (ATR)
- SWBI 0.35
- RGNX 0.52
- MACD
- SWBI 0.15
- RGNX 0.03
- Stochastic Oscillator
- SWBI 76.14
- RGNX 44.06
About SWBI Smith & Wesson Brands Inc.
Smith & Wesson Brands Inc is a U.S.-based leader in firearm manufacturing. It operates under one reportable segment: Firearms, which includes firearms distribution and manufacturing services. The company manufactures handguns, long guns, sporting rifles, shooting gear, and suppressor products. The firm's brand portfolio consists of Smith and Wesson, M&P, Thompson/Center Arms, Performance Center, and Gemtech; which are used for defense, law enforcement, hunting, and sporting purposes. The company operates internationally, with the majority of income generated by the U.S. market from its handgun products.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.